Characterized E2IG3 protein for diagnosis and treatment of proliferative diseases
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Sep 11, 2003
app pub date -
Oct 31, 2002
filing date -
Oct 31, 2001
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The invention relates to the gene encoding the mammalian E2IG3 and its product. More specifically, the invention relates to the diagnosis of aberrant E2IG3 gene or gene product expression, the identification, production, and use of compounds which modulate E2IG3 expression or the activity of the E2IG3 gene product including but not limited to nucleic acid encoding E2IG3 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triplehelix, antibody, and polypeptide molecules as well as small inorganic molecules; and pharmaceutical formulations and routes of administration for such compounds.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully